Funding for New Clean Room Facility
We have received FWO funding 2024-2027 for the infrastructure of our new GMP cleanroom facility cellGENTherapies for the production of advanced medicines in early clinical trials, as well as EFRO funding (RNAvance) for the infrastructure of our new GMP facility to service industrial partners with the production of advanced medicines.
Funding For New Studies
Two main projects for which our facility will manufacture the investigational therapies for clinical use have been granted in 2025, more specifically:
Safety and feasibility study of GALSOME-NEO, a personalized neoantigen targeted mRNA vaccine in patients with locally advanced unresectable PD-L1 negative non-small cell lung cancer (grant Stichting tegen Kanker (STK) and Kom Op Tegen Kanker (KOTK)) in collaboration with Ine Lentacker, Bjorn Menten, Bart Vandekerckhove and Karim Vermaelen.
Development and clinical validation of a personalized mRNA-based cancer vaccine for patients with advanced hepatocellular carcinoma with a grant from Stichting tegen Kanker (STK) and in collaboratoin with Dieter Lambrechts, Jeroen De Kervel and Ine Lentacker.